SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
TEL AVIV, Israel, Sept. 08, 2023. SciSparc Ltd. ( " Company " or " SciSparc " ), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Israel Health | Middle East Health | Pharmaceuticals | Rare Diseases | Tourette Syndrome